Autoimmune disease

T cell therapy in lupus
#Autoimmune disease #Cell therapy #Cullinan Therapeutics #Lupus #Preclinical investigations #T cell engagers

Preclinical data supports T cell engager in autoimmune disease

Positive preclinical data for novel CD19xCD3 T cell engager CLN-978 have supported its potential as a new therapeutic option for autoimmune diseases. Cullinan Therapeutics presented the preclinical results and a study schema for a planned Phase Ib study in patients with moderate to severe systemic lupus… Read More

#News

CAR-T therapy
#Autoimmune disease #CAR-T #Kyverna Therapeutics #Lupus

CAR-T therapy for lupus nephritis “resets the immune system”

Kyverna Therapeutics has revealed plans to present updated clinical data from lupus nephritis (LN) patients treated with KYV-101 at the American College of Rheumatology (ACR) Covergence 2024. The data are from the ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase I/II studies and named patient treatments. Read More

#News #Trending News

#Autoimmune disease #Cell therapy #Immuno-oncology #Kiji Therapeutics #Mergers and acquisitions #Monoclonal antibodies #REGiMMUNE #Stem cells

REGiMMUNE and Kiji Therapeutics announce intention to merge

Biopharmaceutical company REGiMMUNE and biotech Kiji Therapeutics have announced an intention to merge, creating a global Treg specialist that will target multiple indications. The new company, called REGiMMUNE/Kiji TX will combine the complimentary portfolio of platforms and therapies to create an international Treg biotech. Both companies have been focused on… Read More

#Business & Investment #News

CAR-T therapy
#Autoimmune disease #CAR-T #Cell therapy #Kyverna Therapeutics #Multiple sclerosis

New data support CAR-T therapy in neuroinflammatory diseases

Kyverna Therapeutics has revealed continued positive results for its CAR-T therapy KYV-101 in B cell-driven autoimmune diseases. The clinical trial results and case studies were presented in posters and a company-sponsored symposium at the 40th Congress of the European Committee for Treatment and Research in Multiple… Read More

#Editor's Choice #News

#Autoimmune disease #CAR-T #Cell therapy #FDA #Lupus #Synthekine

CAR-T and orthogonal IL-2 therapy for lupus fast-tracked by FDA

The US Food and Drug Administration (FDA) has granted fast track designation to SYNCAR-001 + STK-009. The treatment is indicated for patients with severe, refractory systemic lupus erythematosus (SLE), without the use of lymphodepletion. The fast-track designation follows investigational new drug (IND) clearance for a Phase I study evaluating SYNCAR-001… Read More

#News #Regulatory

#Autoimmune disease #EVOQ Therapeutics #Funding #National Institutes of Health (NIH)

$2 million in funding for autoimmune nanodisc therapies

EVOQ Therapeutics has received a $2 million grant from the National Institutes of Health (NIH) to advance novel therapies for autoimmune diseases. Dr James Moon, Chief Scientific Officer of EVOQ Therapeutics, said: "This support will enable us to accelerate the development of our platform, which we believe could offer significant… Read More

#Business & Investment #News

Arthritis
#Acute inflammatory conditions #Arthritis #Autoimmune disease #Covid-19 #University of Exeter

Breakthrough reveals new drug target for inflammatory diseases

The discovery of a new regulator affecting immune cells could lead to new treatments to reduce inflammation in diseases including arthritis and severe Covid-19. A large research collaboration, led by the University of Exeter’s MRC Centre for Medical Mycology, has focused on how immune cells sense… Read More

#Editor's Choice #News

Lungs
#Autoimmune disease #Clinical trial #GSK #Interview #Lung disease

GSK’s autoimmune efforts

DDW Editor Reece Armstrong speaks to Roger Levy, Global Medical Expert Immunology & Specialty Medicine at GSK about the company’s work into treating systemic sclerosis-associated interstitial lung disease and its recent BLISSc-ILD study evaluating its belimumab treatment.  RA: Can you give us an overview of the BLISSc-ILD study? RL: The BLISSc-ILD study… Read More

#Exclusive Content

CAR-T cell therapy
#Autoimmune disease #CAR-T #Cell therapy #Lupus #Paediatrics #Universitätsklinikum Erlangen

Successful off-label use of CAR-T therapy in a child with lupus

In June 2023, a patient at Universitätsklinikum Erlangen in Germany became the first child with lupus to receive CAR-T therapy. The treatment was the last resort to slow down systemic lupus erythematosus (SLE), which is a serious autoimmune disease that was attacking the patient’s body and… Read More

#Editor's Choice #News

Autoantibodies bond to receptor (achr) blocking the acetylcholine transmitters in Myasthenia gravis (MG).
#Antibody Fragments #argenx #Autoimmune disease #Events #Neurology

Antibody fragment shows promise in myasthenia gravis

argenx shared trial and real-world data on Vyvgart (efgartigimod alfa) in patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive at the European Academy of Neurology (EAN) Annual Meeting. In gMG, Vyvgart demonstrated consistent and repeatable improvements across patient subtypes, a… Read More

#News

Amgen HQ
#Amgen #Autoimmune disease #Immune system #Phase III trial

Amgen reports positive results for treatment of IgG4-RD

Amgen has reported positive topline results from its randomised, double-blind, multicentre, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of its treatment for Immunoglobulin G4-related disease (IgG4-RD). The company’s MITIGATE study was designed to evaluate the safety and efficacy of UPLINZA compared to placebo… Read More

#News

Monoclonal antibody
#Autoimmune disease #Janssen #Monoclonal antibodies #Neurology #Phase III trial

Janssen reports positive data for myasthenia gravis treatment

Janssen-Cilag has reported positive results from its Phase III Vivacity-MG3 study assessing its nipocalimab therapy for the treatment of patients with generalised myasthenia gravis (gMG). The Johnson & Johnson company showcased the data in a presentation at the European Academy of Neurology (EAN) 2024 Congress and… Read More

#News

CAR-T therapy
#Autoimmune disease #CAR-T #Cell therapy #Kyverna Therapeutics #Neurology

First use of CAR-T therapy in patient with stiff-person syndrome

KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, has been used to treat a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS). The therapy was given as part of a named-patient use in Germany for critically ill individuals who fail conventional therapies. Read More

#News

Genomics
#Autoimmune disease #Gastroenterology #Gastrointestinal #IBD #The Francis Crick Institute

Researchers discover genetic cause of bowel diseases

Researchers have discovered a new biological pathway in inflammatory bowel disease (IBD) and related conditions that can be targeted using existing drugs. About 5% of the world’s population are currently affected by an autoimmune disease, such as IBD, the umbrella term for Crohn’s disease and ulcerative… Read More

#Editor's Choice #News

Interleukin-2 conjugate
#Autoimmune disease #Preclinical development #Therapeutic proteins #VALANX Biotech

Study proves efficacy of protein conjugate in autoimmune disease

VALANX Biotech has reported successful in vivo results in its lead programme VLX101 for the treatment of a range of autoimmune diseases. The findings demonstrate the potential of VLX101, a novel Interleukin-2 conjugate and the efficacy of the therapeutic approach. Protein drugs hold great… Read More

#News

#Autoimmune disease #Collaboration #etherna #Hasselt University #Lipid based nanoparticle (LNP) #mRNA

Autoimmune mRNA therapeutics research collaboration 

etherna has entered a research collaboration with Hasselt University (UHasselt) to develop an mRNA based treatment for autoimmune disorders.   Funded by Flanders Innovation & Entrepreneurship (VLAIO), the project aims to combine etherna’s vast expertise in developing customised mRNA and lipid-based nanoparticle technologies for immuno-modulation with UHasselt’s research into autoimmune diseases… Read More

#Business & Investment #News